• Je něco špatně v tomto záznamu ?

Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes

M. Kaiserova, M. Chudackova, H. Prikrylova Vranova, K. Mensikova, A. Kastelikova, D. Stejskal, P. Kanovsky

. 2021 ; 21 (1-2) : 30-35. [pub] 20211025

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012575

BACKGROUND: Various cerebrospinal fluid (CSF) biomarkers are studied in Parkinson's disease (PD) and atypical parkinsonian syndromes (APS). Several studies found reduced 5-hydroxyindoleacetic acid (5-HIAA), the main serotonin metabolite, in PD. There is little evidence regarding its levels in APS. METHODS: We measured 5-HIAA in the CSF of 90 PD patients, 16 MSA patients, 26 progressive supranuclear palsy (PSP) patients, 11 corticobasal syndrome (CBS) patients, and 31 controls. We also compared the values in depressed and nondepressed patients. RESULTS: There was a statistically significant difference in CSF 5-HIAA in PD and MSA compared to the control group (median in PD 15.8 μg/L, in MSA 13.6 μg/L vs. 24.3 μg/L in controls; p = 0.0008 in PD, p = 0.006 in MSA). There was no statistically significant difference in CSF 5-HIAA in PSP and CBS compared to the control group (median in PSP 22.7 μg/L, in CBS 18.7 μg/L vs. 24.3 μg/L in controls; p = 1 in both PSP and CBS). CSF 5-HIAA levels were lower in PD patients with depression compared to PD patients without depression (median 8.34 vs. 18.48, p < 0.0001). CONCLUSIONS: CSF 5-HIAA is decreased in PD and MSA. The CSF 5-HIAA levels in PSP and CBS did not differ from those of the control group. There was a tendency toward lower CSF 5-HIAA in MSA than in PD; however, the results did not reach statistical significance. These results may be explained by more severe damage of the serotonergic system in synucleinopathies (PD and MSA) than in tauopathies (PSP and CBS).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012575
003      
CZ-PrNML
005      
20220506131031.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000520302 $2 doi
035    __
$a (PubMed)34695830
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kaiserova, Michaela $u Department of Neurology, University Hospital Olomouc, Olomouc, Czechia
245    10
$a Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes / $c M. Kaiserova, M. Chudackova, H. Prikrylova Vranova, K. Mensikova, A. Kastelikova, D. Stejskal, P. Kanovsky
520    9_
$a BACKGROUND: Various cerebrospinal fluid (CSF) biomarkers are studied in Parkinson's disease (PD) and atypical parkinsonian syndromes (APS). Several studies found reduced 5-hydroxyindoleacetic acid (5-HIAA), the main serotonin metabolite, in PD. There is little evidence regarding its levels in APS. METHODS: We measured 5-HIAA in the CSF of 90 PD patients, 16 MSA patients, 26 progressive supranuclear palsy (PSP) patients, 11 corticobasal syndrome (CBS) patients, and 31 controls. We also compared the values in depressed and nondepressed patients. RESULTS: There was a statistically significant difference in CSF 5-HIAA in PD and MSA compared to the control group (median in PD 15.8 μg/L, in MSA 13.6 μg/L vs. 24.3 μg/L in controls; p = 0.0008 in PD, p = 0.006 in MSA). There was no statistically significant difference in CSF 5-HIAA in PSP and CBS compared to the control group (median in PSP 22.7 μg/L, in CBS 18.7 μg/L vs. 24.3 μg/L in controls; p = 1 in both PSP and CBS). CSF 5-HIAA levels were lower in PD patients with depression compared to PD patients without depression (median 8.34 vs. 18.48, p < 0.0001). CONCLUSIONS: CSF 5-HIAA is decreased in PD and MSA. The CSF 5-HIAA levels in PSP and CBS did not differ from those of the control group. There was a tendency toward lower CSF 5-HIAA in MSA than in PD; however, the results did not reach statistical significance. These results may be explained by more severe damage of the serotonergic system in synucleinopathies (PD and MSA) than in tauopathies (PSP and CBS).
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a lidé $7 D006801
650    _2
$a kyselina hydroxyindoloctová $7 D006897
650    12
$a multisystémová atrofie $x diagnóza $7 D019578
650    12
$a Parkinsonova nemoc $x diagnóza $7 D010300
650    12
$a parkinsonské poruchy $x metabolismus $7 D020734
650    12
$a progresivní supranukleární obrna $7 D013494
650    12
$a tauopatie $7 D024801
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chudackova, Monika $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia
700    1_
$a Prikrylova Vranova, Hana $u Neurology Outpatient Clinic "St. Moritz", Olomouc, Czechia
700    1_
$a Mensikova, Katerina $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia
700    1_
$a Kastelikova, Anetta $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia
700    1_
$a Stejskal, David $u Institute of Biomedical Sciences, Faculty of Medicine, Ostrava University, Olomouc, Czechia $u Institute of Laboratory Diagnostics, University Hospital Ostrava, Ostrava, Czechia
700    1_
$a Kanovsky, Petr $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia
773    0_
$w MED00180453 $t Neuro-degenerative diseases $x 1660-2862 $g Roč. 21, č. 1-2 (2021), s. 30-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34695830 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131023 $b ABA008
999    __
$a ok $b bmc $g 1789972 $s 1163776
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 21 $c 1-2 $d 30-35 $e 20211025 $i 1660-2862 $m Neuro-degenerative diseases $n Neurodegener Dis $x MED00180453
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

    Možnosti archivace